Evidence grows that melanoma drugs benefit some lung cancer patients
Many patients with BRAF-mutant cancers benefit from treatment with BRAF inhibitors, European researchers report at ELCC
22-Apr-2015 -
A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.Dr. Oliver Gautschi, a ...
dabrafenib
lung cancer
melanoma
+1